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ABSTRACT  
Objective: To evaluate the effect of soy protein isolate (SPI) supplementation on some circulating biomarkers of cardiovascular disease (CVD): total 
homocysteine (tHcy), folate and vitamin B12 in type 2 diabetic patients. Method: Thirty-six type 2 diabetic patients were recruited. They received 
nutrition counseling and were randomized to SPI group (30 g/day of SPI containing 32 mg of isoflavones for 6 weeks) and control group (no SPI 
supplement). Anthropometry, blood pressure and biomarkers of CVD were examined at baseline and at the end of 6th week of the study. Results: 
There were no significant differences in anthropometric parameters, blood pressure and biomarkers of CVD between the 2 groups. At week 6, levels 
of either tHcy, folate, vitamin B12, or GFR between the two groups did not differ. However, in SPI group, tHcy levels were significantly decreased (P 
= 0.005) and folate levels were significantly increased from baseline (P = 0.002). Conclusion: This study indicated that supplementation of SPI with 
isoflavones potentially improves some biomarkers of CVD and may be beneficial on cardiovascular events in type 2 diabetic patients.  
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Introduction 
§Cardiovascular disease (CVD) is a major cause of 
morbidity and mortality among patients with diabetes, 
accounting for more than 80% of death in this population.1,2  
Numerous independent biological factors potentially 
predicting progression to CVD in this population may include 
glycemic control, lipid profile, total homocysteine (tHcy), 
folate and vitamin B12. Circulating tHcy levels were 
significantly elevated in type 2 diabetic patients with 
atherosclerosis vascular disease when compared with those 
without vascular disease. In addition, low folate and vitamin 
B12 levels and reduced renal functions were responsible for 
the majority of elevation of tHcy levels.3  
tHcy, an intermediate sulfur-containing amino acid, is 
formed during the conversion of methionine through re-
methylation pathway which requires folic acid and vitamin 
B12 in this reaction.4 Elevated circulating plasma tHcy levels 
in diabetic patients may contribute to the development of 
chronic complication and a higher rate CVD mortality.5 It has 
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been estimated that lowering plasma tHcy by 5 μmol/l may 
reduce the risk of cardiovascular death by approximately  
10%.6 In type 2 diabetic patients, plasma tHcy levels were 
significantly increased when serum folate and vitamin B12 
levels decreased. Therefore, supplementation of folic acid 
and vitamin B12 in diabetic patients could potentially prevent 
future atherogenic processes and diabetes complications 
due to hyperhomocysteinemia.7 
Soybean is an excellent source of protein, folate, and 
minerals. Soy product intake was inversely associated with 
plasma tHcy and positively correlated with serum folate.8 
Recent studies indicate that genisteine aglycone (54 mg/day) 
supplemented in postmenopausal women significantly 
decreased plasma tHcy compared to placebo after 3 years 
of treatment.9 Turhan et al showed that supplementation of 
isoflavones 80 mg/day in postmenopausal women resulted in 
a significant decrease in plasma tHcy.10 Several studies 
have shown favorable effects of soy protein, isoflavones, or 
both in improved glycemic control and serum lipid profile.11,12 
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There is limited information on the benefits of soy protein 
isolate (SPI) contained isoflavones in reducing other 
biomarkers of CVD (tHcy, folate and vitamin B12), especially 
in diabetes mellitus. The aim of this study was to evaluate 
the effect of SPI supplementation on some circulating 
biomarkers of CVD in type 2 diabetic patients including tHcy, 
folate and vitamin B12, as well as GFR.  
 
Subjects and Methods 
Subjects   
Thirty-six type 2 diabetic patients aged 35 years and 
over with fasting blood sugar (FBS) between 5.56 - 13.89 
mmol/l, and using only sulfonylureas and/or biguanide were 
recruited to participate in this study. All subjects had blood 
pressure (BP) less than 160/100 mmHg, total cholesterol 
(TC) and triglyceride (TG) levels less than 6.21 mmol/l and 
2.26 mmol/l, respectively and body mass index (BMI) 
between 18.5 - 29.9 kg/m2. They also needed to meet the 
following criteria: not taking any antibiotics within the last 7 
days before the study, not taking any nutritional supplements 
or herbal products, soy or soy product regularly, not being a 
vegetarian, not smoking and drinking alcohol regularly. They 
were also free from chronic diseases or conditions including 
liver or renal diseases, history of soy or soy products allergy, 
malnutrition, and surgery within 1 month before and during 
the study. The subjects were randomly divided into 2 groups 
(SPI and control groups) with 18 subjects each. Proportions 
of male and female subjects in the two groups were 
somewhat comparable, 8 males and 10 females in control 
group and 7 males and 11 females in SPI group. The 
experimental protocol was approved by the Ethics 
Committee of Chulalongkorn University, and written informed 
consent was obtained from each subject.   
 
Study Protocol   
In this quasi-experimental study, subjects participated in 
a 10-week experiment with two consecutive periods: a 4-
week pre-experimental period followed by a 6-week experi-
mental period (SPI supplementation). In pre-experimental 
period, subjects received nutrition counseling to control blood 
glucose levels and personal information was obtained. Each 
subject was asked to maintain the amount of energy intake 
and level of physical activity, and to avoid taking additional 
soybean and soy products throughout the study.  
After the pre-experimental period, fasting blood was 
obtained from each subject for determining baseline levels of 
CVD biomarkers including tHcy, folate and vitamin B12. 
Glomerular filtration rate (GFR) was determined using 
Cockroft-Gault formula: GFR (ml/min) = [(140-age) × weight 
(kg)]/[(72 × serum creatinine (mg/dl))] for men, and multiplied 
by 0.85 for women. Habitual diet was assessed by a 3-day 
food record prior to their experimental period and during SPI 
supplementation period. The subjects in SPI group were 
instructed to consume 1 package of 30-g SPI/day (containing 
32 mg isoflavones) for 6 weeks, by mixing with water, soup 
or other beverage. At the end of the study, venous blood 
was drawn after a 12-hour fasting to determine biomarkers 
of CVD, and BP and anthropometric measurements were 
also taken. Plasma tHcy was determined by a fluorescence 
polarization immunoassay using the IMx analyzer. Plasma 
levels of folate and vitamin B12 were determined by 
microbiological assay and Elecsys® immunoassay analyzers, 
respectively. The subject’s compliance was assessed by 
interviewing and counting the remaining packs of SPI. In 
addition, any adverse effects that occurred during SPI 
supplementation were also asked over the telephone. 
 
Statistical Analysis  
Continuous data were expressed as mean ± standard 
deviation (SD). For comparison of the proportion of 
demographic data, chi-square test was used to test for 
significant difference between groups. Normal distribution of 
the data was checked by Shapiro-Wilk’s statistics, skewness, 
and kurtosis. When the distribution of variables was normal, 
paired t-test and independent t-test were used to compare 
within group and between groups differences, respectively. 
Associations between continuous variables were described 
using Pearson’s correlation coefficients. Significance was 
accepted with P < 0.05.  
 
Results  
During the 6-week SPI supplementation, no adverse 
events or side effects of SPI were reported. At baseline, age, 
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BMI, GFR and CVD biomarker levels were comparable 
between SPI and control groups (Table 1).  
 
Table 1 Baseline clinical characteristics of subjects.   
Characteristics 
Mean ± SD 
p-value† Control 
(n = 18) 
Soy protein 
isolate (n = 18) 
    
Age (year) 61.56 ± 10.57 62.00 ± 7.87 0.887 
    
Body mass index (kg/m2) 24.80 ± 2.50 25.55 ± 1.58 0.350 
  
Biomarkers of cardiovascular disease   
Total homocysteine (μmol/l) 12.72 ± 3.50 12.92 ± 4.06 0.200 
Folate (ng/ml) 7.53 ± 4.10 6.91 ± 3.99 0.647 
Vitamin B12 (pg/ml) 433.78 ± 104.19 445.82 ± 112.55 0.741 
    
Glomerular filtration rate 
(ml/min) 
72.16 ± 16.35 71.74 ± 19.74 0.953 
† Independent t-test  
 
In SPI group, at week 6, plasma tHcy levels were 
significantly decreased (P = 0.005) while folate levels were 
significantly increased from baseline (P = 0.002). The effect 
on vitamin B12 was not observed (Table 2). At week 6, levels 
of either tHcy, folate, vitamin B12, or GFR between the two 
groups did not differ. Regarding correlation between tHcy 
and other CVD biomarkers, age and GFR, it was found at 
baseline, circulating tHcy was significantly inversely 
correlated with folate (r = -0.471, P = 0.004), GFR (r = -
0.753, P < 0.001), vitamin B12 (r = -0.390, P = 0.019) and 
significantly positively correlated with age (r = 0.592, P < 
0.001) (Table 3). 
 
Discussion   
In the present study, after 6 weeks of SPI supplement-
ation in type 2 diabetic patients, plasma tHcy levels were 
decreased, whereas plasma folate levels were increased 
from baseline. The intake of 30-g SPI containing 32 mg of 
isoflavones per day was well tolerated and did not cause 
significant side effects.  
An increase in the plasma level of tHcy, an intermediate 
in the catabolism of methionine, has been identified as a risk 
factor for CVD. Elevated tHcy concentrations are associated 
with a higher risk for coronary artery disease (CAD) in 
subject with type 2 diabetes than in non-diabetic subjects.13 
Table 2 Effects of soy protein isolate supplementation on 
biomarkers of cardiovascular disease.   
Parameters  
Mean ± SD 
p-value † Control  
(n = 18) 
Soy protein  
isolate (n = 18) 




Baseline 12.72 ± 3.50 12.92 ± 4.06 
0.090 Week 6 13.60 ± 3.67 11.63 ± 3.22* 
Mean change 0.88 ± 2.07 -1.29 ± 1.72 
     
Folate (ng/ml) Baseline 7.53 ± 4.10 6.91 ± 3.99 
0.353 Week 6 9.44 ± 6.27 10.33 ± 5.36‡ 
Mean change 1.91 ± 5.26 3.42 ± 3.20 
     
Vitamin B12 
(pg/ml) 
Baseline 433.78 ± 104.19 445.82 ± 112.55 
0.657 Week 6 429.71 ± 112.9 444.64 ± 85.11 
Mean change -4.07 ± 95.17 -1.18 ± 85.10 
     
GFR (ml/min) Baseline 72.16 ±16.35 71.96 ± 18.97 
0.975 Week 6 71.77 ± 27.73 71.53 ± 18.80 
Mean change -0.39 ± 18.57 -0.44 ± 5.92 
†Independent t-test comparing between groups at week 6  
* P = 0.005 for significant difference from baseline (within group) (paired t-test)  
‡ P = 0.005 for significant difference from baseline (within group) (paired t-test)  
 
Table 3 Correlations of baseline total homocysteine with age, 
GFR and cardiovascular disease biomarkers (N = 36).  
Biomarker  Pearson’s correlation 
coefficient (r)  
P-value 
   
Folate (ng/ml) -0.471 0.004 
Vitamin B12 (pg/ml) -0.390 0.019 
Age (years) 0.592 < 0.001 
GFR (ml/min) -0.753 < 0.001 
   
 
In this study, baseline tHcy was positively correlated with 
age. The increase in plasma tHcy level with increasing age 
may be due to decreased renal function, decreased B-
vitamins absorption and other factors associated with aging 
process.14 
The amount of tHcy in the blood is regulated by folate, 
vitamin B12 and vitamin B6.15 Lowering tHcy concentrations 
by 25% from current levels would reduce the risk of ischemic 
heart disease by 11%.16 This study found that the supple- 
mentation of SPI for 6 weeks significantly increased plasma 
folate and decreased tHcy concentrations from baseline.  
This study also found that plasma tHcy were significantly 
inversely correlated with folate and vitamin B12. These 
findings are consistent with previous studies in that plasma 
tHcy levels were significantly reduced with soy protein or its 
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isoflavones.8,9 Han et al reported that soy formula-fed infants 
had the highest serum folate than human milk-fed infants.17 
Furthermore, the decrease in plasma tHcy levels in this 
study may be due to the folate in SPI supplemented 
products. Supplementation of folate > 500 μg/d has shown to 
reduce elevated tHcy levels18 and SPI supplemented in this 
study was found to contain folate 211 μg/100 g, which was 
higher than other sources of folate such as kidney beans, 
asparagus and green beans (144, 95 and 37 μg of 
folate/100 g respectively). Moreover, this study found that 
tHcy levels were associated directly with renal functions and 
were increased substantially with a decrease in GFR, the 
indicator of renal function. Mezzano et al showed that 
plasma tHcy was elevated in chronic renal failure patients.20 
Elevation of tHcy found in chronic renal failure was not 
because of impaired urinary excretion but the impaired 
metabolism of tHcy by the kidney instead.21  
 
Conclusion 
The present study has shown that soy protein isolate 
containing isoflavones may have the additional benefits, 
including decreased plasma tHcy and increased folate levels. 
It is thus reasonable to conclude that SPI containing isofla-
vones potentially improves some biomarkers of cardio-
vascular disease in type 2 diabetic patients. However, 
studies with larger subject size and longer period are needed 
before a recommendation on the use of soy protein isolate 
for preventing cardiovascular disease in individuals with high 
risk can be made. 
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